Literature DB >> 26826629

Randomized trial of a multidisciplinary lifestyle intervention in HIV-infected patients with moderate-high cardiovascular risk.

Maria Saumoy1, Carlos Alonso-Villaverde2, Antonio Navarro3, Montserrat Olmo3, Ramon Vila4, Josep Maria Ramon5, Silvana Di Yacovo3, Elena Ferrer3, Jordi Curto3, Antonio Vernet6, Antonia Vila3, Daniel Podzamczer3.   

Abstract

OBJECTIVE: To assess the impact of a multidisciplinary lifestyle intervention on cardiovascular risk and carotid intima-media thickness (c-IMT) in HIV-infected patients with Framingham scores (FS) > 10%.
DESIGN: Randomized pilot study; follow-up 36 months.
METHODS: Virologically suppressed adult HIV-1-infected patients with FS >10% were randomized 1:1 to the intervention group (multidisciplinary lifestyle intervention) or control group (routine care). At baseline and months 12, 24 and 36, lipid parameters were analyzed and carotid ultrasound was performed to determine c-IMT and presence of plaques. Biomarkers were measured at baseline and month 36. The primary endpoints were lipid and FS changes at 36 months.
RESULTS: Fifty-four patients were included, 27 in each arm. Median age was 50.5 years, all patients but one were men, and FS was 16.5%. Relative to controls, total and LDL cholesterol had significantly decreased in the intervention group at 24 months (p = 0.039, p = 0.011, respectively). However, no differences between groups were found at month 36 in lipid variables, neither in FS. Tobacco use decreased in the intervention group (p = 0.031). At baseline, 74.5% of patients had subclinical atherosclerosis, and at month 36, we observed a progression in c-IMT that was greater in the intervention group (p = 0.030). D-dimer increased (p = 0.027) and soluble intercellular adhesion molecule-1 decreased (p = 0.018) at 36 months.
CONCLUSIONS: In this cohort of HIV-infected patients with FS>10% and a high percentage of subclinical atherosclerosis, a multidisciplinary lifestyle intervention resulted in a slight improvement in some cardiovascular risk factors and the FS during the first 2 years, but did not prevent c-IMT progression.
Copyright © 2016 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Biomarkers; Cardiovascular risk; Carotid intima-media thickness; Carotid plaques; Lifestyle intervention

Mesh:

Substances:

Year:  2016        PMID: 26826629     DOI: 10.1016/j.atherosclerosis.2016.01.014

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  9 in total

Review 1.  Contemporary Lifestyle Modification Interventions to Improve Metabolic Comorbidities in HIV.

Authors:  Kathleen V Fitch
Journal:  Curr HIV/AIDS Rep       Date:  2019-12       Impact factor: 5.071

Review 2.  Behavioral Weight Loss: A Promising Treatment for Obesity in Adults with HIV.

Authors:  Emily Panza; Edward J Wing; Rena Wing
Journal:  AIDS Behav       Date:  2020-04

Review 3.  Epidemiology of ischemic heart disease in HIV.

Authors:  Virginia A Triant; Steven K Grinspoon
Journal:  Curr Opin HIV AIDS       Date:  2017-11       Impact factor: 4.283

4.  Cardiovascular Disease Prevention Policy in Human Immunodeficiency Virus: Recommendations From a Modeling Study.

Authors:  Mikaela Smit; Rosan A van Zoest; Brooke E Nichols; Ilonca Vaartjes; Colette Smit; Marc van der Valk; Ard van Sighem; Ferdinand W Wit; Timothy B Hallett; Peter Reiss
Journal:  Clin Infect Dis       Date:  2018-02-10       Impact factor: 9.079

5.  Role of systemic inflammation scores for prediction of clinical outcomes in patients treated with atazanavir not boosted by ritonavir in the Italian MASTER cohort.

Authors:  Maria Concetta Postorino; Mattia Prosperi; Emanuele Focà; Eugenia Quiros-Roldan; Elisa Di Filippo; Franco Maggiolo; Alberto Borghetti; Nicoletta Ladisa; Massimo Di Pietro; Andrea Gori; Laura Sighinolfi; Angelo Pan; Nicola Mazzini; Carlo Torti
Journal:  BMC Infect Dis       Date:  2017-03-15       Impact factor: 3.090

6.  HIV disease, metabolic dysfunction and atherosclerosis: A three year prospective study.

Authors:  Hann Low; Anh Hoang; Tatiana Pushkarsky; Larisa Dubrovsky; Elizabeth Dewar; Maria-Silvana Di Yacovo; Nigora Mukhamedova; Lesley Cheng; Catherine Downs; Gary Simon; Maria Saumoy; Andrew F Hill; Michael L Fitzgerald; Paul Nestel; Anthony Dart; Jennifer Hoy; Michael Bukrinsky; Dmitri Sviridov
Journal:  PLoS One       Date:  2019-04-18       Impact factor: 3.240

Review 7.  What happens to cardiovascular system behind the undetectable level of HIV viremia?

Authors:  Gabriella d'Ettorre; Giancarlo Ceccarelli; Paolo Pavone; Pietro Vittozzi; Gabriella De Girolamo; Ivan Schietroma; Sara Serafino; Noemi Giustini; Vincenzo Vullo
Journal:  AIDS Res Ther       Date:  2016-04-27       Impact factor: 2.250

8.  Effects of aerobic and resistance exercise alone or combined on strength and hormone outcomes for people living with HIV. A meta-analysis.

Authors:  Camilo Germán Alberto Pérez Chaparro; Philipp Zech; Felipe Schuch; Bernd Wolfarth; Michael Rapp; Andreas Heiβel
Journal:  PLoS One       Date:  2018-09-04       Impact factor: 3.240

9.  Reducing cardiovascular risk among people living with HIV: Rationale and design of the INcreasing Statin Prescribing in HIV Behavioral Economics REsearch (INSPIRE) randomized controlled trial.

Authors:  Sae Takada; Allison J Ober; Judith S Currier; Noah J Goldstein; Tamara B Horwich; Brian S Mittman; Suzanne B Shu; Chi-Hong Tseng; Tara Vijayan; Soma Wali; William E Cunningham; Joseph A Ladapo
Journal:  Prog Cardiovasc Dis       Date:  2020-02-19       Impact factor: 8.194

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.